Spero Therapeutics Stock Market Value
| SPRO Stock | USD 2.39 0.01 0.42% |
| Symbol | Spero |
Will Biotechnology sector continue expanding? Could Spero diversify its offerings? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spero Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.753 | Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets |
Understanding Spero Therapeutics requires distinguishing between market price and book value, where the latter reflects Spero's accounting equity. The concept of intrinsic value - what Spero Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spero Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spero Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Spero Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Spero Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Spero Therapeutics.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Spero Therapeutics on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Spero Therapeutics or generate 0.0% return on investment in Spero Therapeutics over 90 days. Spero Therapeutics is related to or competes with Seres Therapeutics, VistaGen Therapeutics, Actuate Therapeutics, Inovio Pharmaceuticals, Acumen Pharmaceuticals, Seer, and Cognition Therapeutics. Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercial... More
Spero Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Spero Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Spero Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 13.07 | |||
| Value At Risk | (5.04) | |||
| Potential Upside | 3.81 |
Spero Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spero Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Spero Therapeutics' standard deviation. In reality, there are many statistical measures that can use Spero Therapeutics historical prices to predict the future Spero Therapeutics' volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.25) | |||
| Treynor Ratio | (0.03) |
Spero Therapeutics February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.02) | |||
| Mean Deviation | 2.09 | |||
| Coefficient Of Variation | (9,080) | |||
| Standard Deviation | 2.76 | |||
| Variance | 7.62 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.25) | |||
| Treynor Ratio | (0.03) | |||
| Maximum Drawdown | 13.07 | |||
| Value At Risk | (5.04) | |||
| Potential Upside | 3.81 | |||
| Skewness | (0.29) | |||
| Kurtosis | 0.7474 |
Spero Therapeutics Backtested Returns
As of now, Spero Stock is relatively risky. Spero Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of close to zero, which indicates the firm had a close to zero % return per unit of risk over the last 3 months. We have found twenty-two technical indicators for Spero Therapeutics, which you can use to evaluate the volatility of the company. Please validate Spero Therapeutics' insignificant Risk Adjusted Performance, coefficient of variation of (9,080), and Variance of 7.62 to confirm if the risk estimate we provide is consistent with the expected return of 0.0055%. The entity has a beta of 1.45, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Spero Therapeutics will likely underperform. Spero Therapeutics right now has a risk of 2.58%. Please validate Spero Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to decide if Spero Therapeutics will be following its existing price patterns.
Auto-correlation | 0.00 |
No correlation between past and present
Spero Therapeutics has no correlation between past and present. Overlapping area represents the amount of predictability between Spero Therapeutics time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Spero Therapeutics price movement. The serial correlation of 0.0 indicates that just 0.0% of current Spero Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.12 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Pair Trading with Spero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Spero Stock
| 0.44 | DNLI | Denali Therapeutics | PairCorr |
| 0.42 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.4 | SAB | Sonic Healthcare Earnings Call This Week | PairCorr |
| 0.39 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.36 | DSGN | Design Therapeutics | PairCorr |
The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.
The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Spero Therapeutics Correlation, Spero Therapeutics Volatility and Spero Therapeutics Performance module to complement your research on Spero Therapeutics. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Spero Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.